Lexicon Pharmaceuticals (LXRX) Misses Q1 View By 3c
More News related to LXRX
- Lexicon Pharma (LXRX) Posts Q3 Loss of $0.14
- Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Third Quarter Financial Results
- Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
- Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2009 Financial Results on October 27, 2009
- Lexicon Announces Completion of Public Offering of Common Stock
Lexicon Pharmaceuticals (Nasdaq: LXRX) reports Q1 LOSS of $0.16, 3 cents below the analyst estimate of ($0.13). Revenue for the quarter was $4.2 million, versus the consensus of $5.96 million.
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
